Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Carboplatin 14pembrolizumab 12Gemcitabine 11Cisplatin 11Rituximab 8durvalumab 7Pemetrexed 6Nivolumab 6osimertinib 5atezolizumab 5Specimen Handling 5Paclitaxel 5Dexamethasone 5amivantamab 4Prednisone 4Ipilimumab 4Cyclophosphamide 4Bortezomib 4Bendamustine Hydrochloride 4tremelimumab 3trastuzumab deruxtecan 3olaparib 3niraparib 3lazertinib 3entrectinib 3enfortumab vedotin 3daratumumab 3belzutifan 3alectinib 3acalabrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × luprolide acetate gel depot × 90 days × Clear all
NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Pfizer

Phase 3 Active not recruiting
1,068 enrolled 20 charts 1 FDA
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡